摘要
瑞舒伐他汀是目前为止公认的性价比较高的一类调脂药物,它的调脂和非调脂功能已逐渐被大家认可,并广泛应用于心血管疾病及代谢综合征的预防和治疗。与此同时,瑞舒伐他汀主要经细胞色素P450同工酶2C9和2C19进行缓慢代谢,与抗精神病药物间相互作用小,可广泛应用于精神科。然而,目前精神领域对瑞舒伐他汀的研究仅局限于其降脂功能,其非调脂功能研究较少。
Rosuvastatin is now recognized as the lipid regulation agent of good price/performance, and its blood-fat regulation function and non-blood-fat regulation function have been gradually recognized, and it has been used in the prevention and treatment of cardiovascular disease and metabolic syndrome. At the same time, rosuvastatin mainly metabolizes slowly by cytochreme P450 isoenzyme 2C9 and 2C19,with less interactions with antipsychotic drugs,so it can be used widely in psychiatry clinic. However,the current rosuvastatin studies in psychiatry are limited to the lipid-lowering function, while its non-blood-fat regulation function is rarely touched.
出处
《医学综述》
2016年第13期2603-2606,共4页
Medical Recapitulate
